NewcelX submits FDA pre-IND package for NCEL-101 type 1 diabetes trial
PUBT · 05/27 11:55
Share
Listen to the news
- NewcelX submitted a pre-IND briefing package to the FDA for NCEL-101 in type 1 diabetes, targeting a first-in-human trial.
- A Type B pre-IND meeting is scheduled for the last week of June to review manufacturing, preclinical plans, trial design.
- Program pairs NCEL-101 with Eledon’s tegoprubart as part of a calcineurin inhibitor-free immunosuppression regimen.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270755PRIMZONEFULLFEED9727200) on May 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending